Zymeworks (ZYME) to Release Quarterly Earnings on Wednesday

Zymeworks (NASDAQ:ZYME) is expected to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Zymeworks to post earnings of ($0.35) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Zymeworks Stock Up 2.8%

Shares of ZYME stock opened at $23.63 on Wednesday. The business has a 50-day moving average price of $24.14 and a two-hundred day moving average price of $20.59. Zymeworks has a 12-month low of $9.03 and a 12-month high of $28.49. The firm has a market cap of $1.77 billion, a P/E ratio of -28.13 and a beta of 1.25.

Insider Activity

In other news, COO Mark Hollywood sold 6,120 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $22.67, for a total transaction of $138,740.40. Following the completion of the transaction, the chief operating officer directly owned 132,913 shares of the company’s stock, valued at approximately $3,013,137.71. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey T. L. Smith sold 9,310 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $211,057.70. Following the sale, the executive vice president owned 26,708 shares of the company’s stock, valued at approximately $605,470.36. This represents a 25.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 187,933 shares of company stock valued at $4,673,716. 33.51% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its position in shares of Zymeworks by 175.0% in the 4th quarter. Invesco Ltd. now owns 257,580 shares of the company’s stock worth $6,782,000 after buying an additional 163,923 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Zymeworks during the fourth quarter valued at approximately $2,461,000. VARCOV Co. bought a new stake in Zymeworks in the fourth quarter valued at $259,000. Virtus Investment Advisers LLC boosted its holdings in Zymeworks by 20.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,441 shares of the company’s stock valued at $275,000 after acquiring an additional 1,755 shares in the last quarter. Finally, SummitTX Capital L.P. purchased a new position in Zymeworks during the 4th quarter valued at $5,905,000. Institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

ZYME has been the subject of several research reports. Zacks Research lowered Zymeworks from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Wall Street Zen lowered shares of Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Stifel Nicolaus increased their target price on shares of Zymeworks from $30.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Citizens Jmp set a $32.00 target price on shares of Zymeworks in a research report on Wednesday, December 3rd. Finally, B. Riley Financial restated a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Zymeworks in a research report on Friday, November 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.90.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.